Pharmacogenomics of Selective Serotonin Reuptake Inhibitor Treatment for Major Depressive Disorder: Genome-wide Associations and Functional Genomics

Overview

Journal Pharmacogenomics J

Specialties Genetics
Molecular Biology
Pharmacology

Date 2012 Aug 22

PMID 22907730

Citations 40

Authors

Y Ji

J M Biernacka

S Hebbring

Y Chai

G D Jenkins

A Batzler

K A Snyder

M S Drews

Z Desta

D Flockhart

T Mushiroda

M Kubo

Y Nakamura

N Kamatani

D Schaid

R M Weinshilboum

D A Mrazek

Affiliations

Soon will be listed here.

Abstract

A genome-wide association (GWA) study of treatment outcomes (response and remission) of selective serotonin reuptake inhibitors (SSRIs) was conducted using 529 subjects with major depressive disorder. While no SNP associations reached the genome-wide level of significance, 14 SNPs of interest were identified for functional analysis. The rs11144870 SNP in the riboflavin kinase (RFK) gene on chromosome 9 was associated with 8-week treatment response (odds ratio (OR)=0.42, P=1.04 × 10⁻⁶). The rs915120 SNP in the G protein-coupled receptor kinase 5 (GRK5) gene on chromosome 10 was associated with 8-week remission (OR=0.50, P=1.15 × 10⁻⁵). Both SNPs were shown to influence transcription by a reporter gene assay and to alter nuclear protein binding using an electrophoretic mobility shift assay. This report represents an example of joining functional genomics with traditional GWA study results derived from a GWA analysis of SSRI treatment outcomes. The goal of this analytical strategy is to provide insights into the potential relevance of biologically plausible observed associations.

Citing Articles

Flavins and Flavoproteins in the Neuroimmune Landscape of Stress Sensitization and Major Depressive Disorder.

Schrier M, Smirnova M, Nemeth D, Deth R, Quan N J Inflamm Res. 2025; 18:681-699.

PMID: 39839188 PMC: 11748166. DOI: 10.2147/JIR.S501652.

Precision Medicine in Antidepressants Treatment.

Tsermpini E, Serretti A, Dolzan V Handb Exp Pharmacol. 2023; 280:131-186.

PMID: 37195310 DOI: 10.1007/164_2023_654.

Investigating genetic variants for treatment response to selective serotonin reuptake inhibitors in syndromal factors and side effects among patients with depression in Taiwanese Han population.

Huang S, Chen Y, Su M, Tsai S, Chen H, Yang A Pharmacogenomics J. 2023; 23(2-3):50-59.

PMID: 36658263 DOI: 10.1038/s41397-023-00298-8.

Network science approach elucidates integrative genomic-metabolomic signature of antidepressant response and lifetime history of attempted suicide in adults with major depressive disorder.

Grant C, Wilton A, Kaddurah-Daouk R, Skime M, Biernacka J, Mayes T Front Pharmacol. 2022; 13:984383.

PMID: 36263124 PMC: 9573988. DOI: 10.3389/fphar.2022.984383.

Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder.

Grant C, Barreto E, Kumar R, Kaddurah-Daouk R, Skime M, Mayes T J Pers Med. 2022; 12(3).

PMID: 35330412 PMC: 8949112. DOI: 10.3390/jpm12030412.

References

Reynolds E, Carney M, Toone B . Methylation and mood. Lancet. 1984; 2(8396):196-8. DOI: 10.1016/s0140-6736(84)90482-3. View

Tiberi M, Nash S, Bertrand L, Lefkowitz R, Caron M . Differential regulation of dopamine D1A receptor responsiveness by various G protein-coupled receptor kinases. J Biol Chem. 1996; 271(7):3771-8. DOI: 10.1074/jbc.271.7.3771. View

Dickel D, Veenstra-VanderWeele J, Bivens N, Wu X, Fischer D, Van Etten-Lee M . Association studies of serotonin system candidate genes in early-onset obsessive-compulsive disorder. Biol Psychiatry. 2007; 61(3):322-9. DOI: 10.1016/j.biopsych.2006.09.030. View

Gaysina D, Cohen-Woods S, Chow P, Martucci L, Schosser A, Ball H . Association analysis of DAOA and DAO in bipolar disorder: results from two independent case-control studies. Bipolar Disord. 2010; 12(5):579-81. DOI: 10.1111/j.1399-5618.2010.00837.x. View

Garriock H, Kraft J, Shyn S, Peters E, Yokoyama J, Jenkins G . A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry. 2009; 67(2):133-8. PMC: 2794921. DOI: 10.1016/j.biopsych.2009.08.029. View

Lewis S, Lawlor D, Davey Smith G, Araya R, Timpson N, Day I . The thermolabile variant of MTHFR is associated with depression in the British Women's Heart and Health Study and a meta-analysis. Mol Psychiatry. 2006; 11(4):352-60. DOI: 10.1038/sj.mp.4001790. View

Schumacher J, Jamra R, Freudenberg J, Becker T, Ohlraun S, Otte A . Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol Psychiatry. 2004; 9(2):203-7. DOI: 10.1038/sj.mp.4001421. View

Motsinger-Reif A, Jorgenson E, Relling M, Kroetz D, Weinshilboum R, Cox N . Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics. 2010; 23(8):383-94. PMC: 3003940. DOI: 10.1097/FPC.0b013e32833d7b45. View

Mekli K, Payton A, Miyajima F, Platt H, Thomas E, Downey D . The HTR1A and HTR1B receptor genes influence stress-related information processing. Eur Neuropsychopharmacol. 2010; 21(1):129-39. DOI: 10.1016/j.euroneuro.2010.06.013. View

10.

Uher R, Perroud N, Ng M, Hauser J, Henigsberg N, Maier W . Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010; 167(5):555-64. DOI: 10.1176/appi.ajp.2009.09070932. View

11.

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D . PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81(3):559-75. PMC: 1950838. DOI: 10.1086/519795. View

12.

Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N . A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009; 5(3):e1000433. PMC: 2652833. DOI: 10.1371/journal.pgen.1000433. View

13.

Wang X, He G, Gu N, Yang J, Tang J, Chen Q . Association of G72/G30 with schizophrenia in the Chinese population. Biochem Biophys Res Commun. 2004; 319(4):1281-6. DOI: 10.1016/j.bbrc.2004.05.119. View

14.

Villafuerte S, Vallabhaneni K, Sliwerska E, McMahon F, Young E, Burmeister M . SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet. 2009; 19(6):281-91. PMC: 2783179. DOI: 10.1097/YPG.0b013e32832a506e. View

15.

Niu N, Qin Y, Fridley B, Hou J, Kalari K, Zhu M . Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res. 2010; 20(11):1482-92. PMC: 2963812. DOI: 10.1101/gr.107672.110. View

16.

Thase M, Haight B, Richard N, Rockett C, Mitton M, Modell J . Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005; 66(8):974-81. DOI: 10.4088/jcp.v66n0803. View

17.

Ji Y, Hebbring S, Zhu H, Jenkins G, Biernacka J, Snyder K . Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther. 2010; 89(1):97-104. PMC: 3034442. DOI: 10.1038/clpt.2010.250. View

18.

Laje G, McMahon F . Genome-wide association studies of antidepressant outcome: a brief review. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 35(7):1553-7. PMC: 3125482. DOI: 10.1016/j.pnpbp.2010.11.031. View

19.

Marchetto M, Brennand K, Boyer L, Gage F . Induced pluripotent stem cells (iPSCs) and neurological disease modeling: progress and promises. Hum Mol Genet. 2011; 20(R2):R109-15. PMC: 4447776. DOI: 10.1093/hmg/ddr336. View

20.

Ising M, Lucae S, Binder E, Bettecken T, Uhr M, Ripke S . A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009; 66(9):966-975. PMC: 4465570. DOI: 10.1001/archgenpsychiatry.2009.95. View